Actelion contracted Digital Hive Mind for a series of images to support the November 18th launch of their newest product, Valchlor, the first and only FDA-approved topical treatment for cutaneous T-cell lymphoma, a rare form of cancer which affects approximately 20,000 patients in the U.S.

Due to the extremely sensitive nature of the product, Digital Hive Mind staged the photo shoot on-site in a clean room at the contract packaging facility.